<DOC>
	<DOCNO>NCT01850979</DOCNO>
	<brief_summary>Aqueous deficiency dry eye mainly cause Sjogren syndrome ( SS ) , autoimmune , chronic , inflammatory systemic disease affect commonly lacrimal salivary glands.The ocular treatment focus increase lubrification decrease inflammation topical autologous serum , topical immunosuppressive agent corticotherapy . Use topical immunosuppressant increase recent year topical corticotherapy lead ocular complication . The used immunosuppressant cyclosporine . Tacrolimus , another immunosuppressant , use treatment immune inflammatory ocular diseases.This study describe prospective control double-blinded randomized study clinical outcome SS dry eye patient treat 0.03 % tacrolimus eye drop . As secondary purpose , outcome dry eye symptom ocular symptom eye drop also question patient .</brief_summary>
	<brief_title>Treatment Dry Eye Using 0.03 % Tacrolimus Eye Drops</brief_title>
	<detailed_description>Aqueous deficiency dry eye mainly cause Sjogren syndrome ( SS ) , autoimmune , chronic , inflammatory systemic disease affect commonly lacrimal salivary gland . The hyperreactivity B lymphocytes cause lymphoplasmacytic infiltration , induces production antibody antigens acinar epithelium duct lacrimal exocrine gland . The ocular treatment focus increase lubrification decrease inflammation topical autologous serum , topical immunosuppressive agent corticotherapy . Use topical immunosuppressant increase recent year topical corticotherapy lead ocular complication . Among topical immunosuppressant use one tacrolimus , also know FK506 cyclosporine A ( CsA ) . Their mechanism action similar , FK 506 describe 10 100 time potent CsA . Tacrolimus macrolide immunomodulatory action become biologically active bind immunophilin act inhibit calcineurin , limit transduction signal carry information cell membrane nucleus , aim stimulate interleukin ( IL ) - 2 synthesis , inhibit T B lymphocyte activation . Generally , tacrolimus suppresses immune response inhibit release inflammatory cytokine ( eg , IL-3 , IL-4 , IL-5 , IL-8 , interferon- ϒ , tumor necrosis factor - α ) . The systemic topical use tacrolimus already well establish ophthalmologic treatment immune-mediated disease , uveitis , graft-versus-host disease , corneal transplant ocular pemphigoid . In veterinary medicine , topical tacrolimus aqueous suspension well establish treat dry eye dog . In human , tacrolimus eye drop report effective treating severe allergic conjunctivitis . In previous report , group show clinical outcome case series eight patient dry eye use 0.03 % tacrolimus eye drop 5 base evidence treat animal KCS . This study describe prospective control double-blinded randomized study clinical outcome SS dry eye patient treat 0.03 % tacrolimus eye drop . As secondary purpose , outcome dry eye symptom ocular symptom eye drop also question patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>SS diagnose accord SS European Criteria chronic symptom burn , foreign body sensation , itch eye daily need artificial tear abnormal Schirmer ( ST ) I test &lt; 5mm rise Bengal stain ( RBS ) ≥ 4 , break time ( BUT ) &lt; 5 second . structural abnormality ( lid scarring , entropion , trichiasis , etc . ) inflammation active structural change iris anterior chamber glaucoma previous eye surgery punctual occlusion use topical medication artificial tear systemic topical antibacterial antiinflammatory drug treatment 90 day study entry contact lens wearer presence corneal infection corneal disease ( marginal ulcer , opacity , scar , bullous keratopathy , conjunctivochalasis , symblepharon tumor ) pregnancy change immunosuppressive systemic therapy 90 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>CYCLOSPORINE/TACROLIMUS [ VA Drug Interaction ]</keyword>
</DOC>